Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary statement from the international mesothelioma interest group, also endorsed by the international academy of cytology and the papanicolaou society of cytopathology

Acta Cytologica

Volumn 59, Issue 1, 2015, Pages 2-16

  Hjerpe, Anders ^a   Ascoli, Valeria ^b   Bedrossian, Carlos W M ^c   Boon, Mathilde E ^d   Creaney, Jenette ^e   Davidson, Ben ^f   Dejmek, Annika ^g   Dobra, Katalin ^a   Fassina, Ambrogio ^h   Field, Andrew ⁱ   Firat, Pinar ^j   Kamei, Toshiaki ^k   Kobayashi, Tadao ^l   Michael, Claire W ^m   Önder, Sevgen ⁿ   Segal, Amanda ^o   Vielh, Philippe ^p  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c RUSH MEDICAL COLLEGE   (United States)

^d LEIDEN CYTOLOGY AND PATHOLOGY LABORATORY   (Netherlands)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g LUND UNIVERSITY   (Sweden)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j ISTANBUL UNIVERSITY   (Turkey)

^k Yamaguchi Grand Medical Center   (Japan)

^l OSAKA UNIVERSITY   (Japan)

^m UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁿ HACETTEPE UNIVERSITY   (Turkey)

^o PATHWEST LABORATORY MEDICINE   (Australia)

^p INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Ancillary testing; Cytology; Guidelines; International Mesothelioma Interest Group; Malignant mesothelioma

Indexed keywords

CANCER PATIENT; CELL STRUCTURE; CYTOPATHOLOGY; DIFFERENTIAL DIAGNOSIS; ELECTRON MICROSCOPY; EPITHELIOID MALIGNANT MESOTHELIOMA; FOLLOW UP; FRANCE; HUMAN; MALIGNANT MESOTHELIOMA; MIXED TYPE MALIGNANT MESOTHELIOMA; MOLECULAR BIOLOGY; PEER REVIEW; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCIENTIST; UNITED STATES; CYTODIAGNOSIS; IMMUNOHISTOCHEMISTRY; INTERNATIONAL COOPERATION; LUNG NEOPLASMS; MEDICAL SOCIETY; MESOTHELIOMA; METABOLISM; PATHOLOGY; PROCEDURES; ULTRASTRUCTURE;

TUMOR MARKER;

CYTODIAGNOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNATIONALITY; LUNG NEOPLASMS; MESOTHELIOMA; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84928424993     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000377697     Document Type: Review

References (49)

1. Husain AN, Colby TV, et al: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331
2. Husain AN, Colby T, et al: Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013; 137: 647-667
3. Rakha EA, Patil S, et al: The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol 2010; 38: 874-879
4. Paintal A, Raparia K, et al: The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Cancer Cytopathol 2013; 121: 703-707
5. Segal A, Sterrett GF, et al: A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 2013; 45: 44-48
6. Sheaff M: Should cytology be an acceptable means of diagnosing malignant mesothelioma? Cytopathology 2011; 22: 3-4
7. Henderson DW, Reid G, et al: Challenges and controversies in the diagnosis of mesothelioma. Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 2013; 66: 847-853
8. Whitaker D: The cytology of malignant mesothelioma. Cytopathology 2000; 11: 139-151
9. Bedrossian CWM: Malignant Effusions: A Multimodal Approach to Cytologic Diagnosis. New York, Igaku Shoin, 1994
10. Tao L: Cytopathology of Malignant Effusions. Chicago, ASCP Press, 1996
11. Davidson B, Firat P, et al (eds): Serous Effusions: Etiology, Diagnosis, Prognosis, and Therapy. London/New York, Springer, 2012
12. Michael CW, Chhieng D, Bedrossian CWM (eds): Cytohistology of the Serous Membranes. New York, Cambridge University Press, 2015
13. Zellos LS, Sugarbaker DJ: Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 2002; 29: 41-50
14. Ismail-Khan R, Robinson LA, et al: Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006; 13: 255-263
15. Michael CW, Bedrossian CC: The implementation of liquid-based cytology for lung and pleural-based diseases. Acta Cytol 2014; 58: 563-573
16. Widehn S, Kindblom LG: A rapid and simple method for electron microscopy of paraffinembedded tissue. Ultrastruct Pathol 1988; 12: 131-136
17. Kwee WS, Veldhuizen RW, et al: Quantitative and qualitative differences between benign and malignant mesothelial cells in pleural fluid. Acta Cytol 1982; 26: 401-406
18. Matsumoto S, Nabeshima K, et al: Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol 2013; 121: 415-422
19. Kho-Duffin J, Tao LC, et al: Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type. Diagn Cytopathol 1999; 20: 57-62
20. Boon ME, van Velzen D, et al: Analysis of number, size and distribution patterns of lipid vacuoles in benign and malignant mesothelial cells. Anal Quant Cytol 1984; 6: 221-226
21. Boon ME, Veldhuizen RW, et al: Qualitative distinctive differences between the vacuoles of mesothelioma cells and of cells from metastatic carcinoma exfoliated in pleural fluid. Acta Cytol 1984; 28: 443-449
22. Leong AS, Parkinson R, et al: 'Thick' cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma. Diagn Cytopathol 1990; 6: 9-13
23. Ordonez NG, Sahin AA: Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Hum Pathol 2014; 45: 1529-1540
24. Dejmek A, Hjerpe A: Carcinoembryonic antigen-like reactivity in malignant mesothelioma: a comparison between different commercially available antibodies. Cancer 1994; 73: 464-469
25. Dejmek A, Hjerpe A: Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000; 11: 8-17
26. Saad RS, Cho P, et al: The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 2005; 32: 156-159
27. Sato A, Torii I, et al: Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 2010; 23: 1458-1466
28. Husain AN, Mirza MK, et al: How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study. Lung Cancer 2014; 83: 324-328
29. Minato H, Kurose N, et al: Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am J Clin Pathol 2014; 141: 85-93
30. Hasteh F, Lin GY, et al: The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010; 118: 90-96
31. Churg A, Allen T, et al: Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol 2014; 38: 990-998
32. Washimi K, Yokose T, et al: Well-differentiated papillary mesothelioma, possibly giving rise to diffuse malignant mesothelioma: a case report. Pathol Int 2013; 63: 220-225
33. Davidson B: The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma. Cytopathology 2011; 22: 5-21
34. Baker PM, Clement PB, et al: Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123: 724-737
35. Robinson BW, Creaney J, et al: Mesothelinfamily proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616
36. Creaney J, Yeoman D, et al: Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007; 62: 569-576
37. Pass HI, Wali A, et al: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85: 265-272
38. Creaney J, Dick IM, et al: Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer 2013; 82: 491-498
39. Fujimoto N, Gemba K, et al: Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma. Respir Investig 2013; 51: 92-97
40. Mundt F, Nilsonne G, et al: Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One 2013; 8:e72030
41. Benjamin H, Lebanony, et al: A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn 2010; 12: 771-779
42. Bovin N, Obukhova P, et al: Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies? Biochim Biophys Acta 2012; 1820: 1373-1382
43. Pass HI, Levin SM, et al: Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417-1427
44. Nurminen M, Dejmek A, et al: Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content. Clin Chem 1994; 40: 777-780
45. Wan C, Shen YC, et al: Diagnostic value of fluorescence in situ hybridization assay in malignant mesothelioma: a meta-analysis. Asian Pac J Cancer Prev 2012; 13: 4745-4749
46. Adell E, Dejmek A: Telomerase activity analyzed with trap in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis. Diagn Cytopathol 2014; 42: 1051-1057
47. Zendehrokh N, Dejmek A: Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes. Mod Pathol 2005; 18: 189-196
48. Flores-Staino C, Darai-Ramqvist E, et al: Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer 2010; 68: 39-43
49. Pinelli V, Laroumagne S, et al: Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 595-598.